Rapamycin-induced g1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin

Blood

Volumn 101, Issue 1, 2003, Pages 278-285

  Decker, Thomas ^a   Hipp, Susanne ^a   Ringshausen, Ingo ^a   Bogner, Christian ^a   Oelsner, Madlene ^a   Schneller, Folker ^a   Peschel, Christian ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN D2; CYCLIN D3; CYCLIN E; INTERLEUKIN 2; OLIGONUCLEOTIDE; RAPAMYCIN; RETINOBLASTOMA PROTEIN; SURVIVIN; ANTINEOPLASTIC ANTIBIOTIC; BIRC5 PROTEIN, HUMAN; CYCLINE; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; B CELL LEUKEMIA; B LYMPHOCYTE; CULTURE TECHNIQUE; DRUG EFFECT; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; B-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL CYCLE; CYCLIN A; CYCLIN E; CYCLINS; G1 PHASE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; SIROLIMUS;

EID: 0037207525     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0189     Document Type: Article

References (64)

1. Meinhardt G, Wendtner CM, Hallek M. Molecular pathogenesis of chronic lymphocytic leukemia: Factors and signaling pathways regulating cell growth and survival. J Mol Med. 1999;77:282-293.
2. Vrhovac R, Delmer A, Tang R, Marie JP, Zittuon R, Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27 in chronic B-cell lymphocytic leukemia. Blood. 1998;91:4694-4700.
3. Qintanilla-Martinez LC, Thieblemont S, Fend F, et al. Mantle cell lymphoma lack expression of p27kip1, a cyclin-dependent kinase inhibitor. Am J Pathol. 1998;153:175-182.
4. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 2001;97:2777-2783.
5. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
6. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396:580-584.
7. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: A bird of a different feather. J Clin Oncol. 1999;17:399-408.
8. Decker T, Flohr T, Trautmann P, et al. Role of accessory cells in cytokine production by T cells in chronic B-cell lymphocytic leukemia. Blood. 1995;86:1115-1123.
9. Tretter T, Brass U, Schuler M, et al. Direct cellular interaction with activated CD4+ T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro. Cell Immunol. 1998;189:41-50.
10. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993;177:925-935.
11. Lankester AC, van Schijndel GM, van der Schoot CE, van Oers MH, van Noesel CJ, van Lier RA. Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. Blood. 1995;86:1090-1097.
12. Fluckiger AC, Rossi JF, Bussel A, Bryon P, Bancherau J, Defrance T. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood. 1992;80:3173-3181.
13. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky P. Activation of human B cells by phosphorothioate oligonucleotides. J Clin Invest. 1996;98:1119-1129.
14. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000;164:944-953.
15. Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine secretion and an immunogenic phenotype in B-CLL patients. Blood. 2000;95:999-1006.
16. Decker T, Schneller F, Kronschnabl M, et al. Immunostimulatory CpG-oligonucleotides induce the expression of functional IL-2 receptors on B-CLL cells: Costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol. 2000;28:558-568.
17. Decker T, Schneller F, Hipp S, et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia. 2002;16:327-334.
18. Abraham RT. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol. 1998;10:330-336.
19. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolismus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001;71:271-280.
20. Kahan BD. Efficacy of sirolismus compared with azathioprine for reduction of acute renal allograft rejection - A randomized multicentre study: The Rapamune US study group. Lancet. 2000;356:194-202.
21. Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature. 1989;341:755-757.
22. Jefferies HBJ, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′ TOP mRNA translation through inhibition of p70s6k. Embo J. 1997;16:3693-3704.
23. Raught B, Gingras AC, Sonnenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci U S A. 2001;98:7037-7044.
24. Gingras AC, Gygi SP, Raught B, et al. Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism. Genes Dev. 1999;13:1422-1437.
25. Wicker SL, Boltz RC, Matt V, Nichols EA, Peterson LB, Sigal NH. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol. 1990;20:2277-2283.
26. 1 arrest in exponentially growing T-cell lines. Blood. 1998;91:561-569.
27. Shi Y, Frankel A, Radvanyi AG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. 1996;55:1982-1988.
28. Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res. 1996;56:3895-3897.
29. Hosoi H, Dilling MB, Shikata T, et al.Rapamycin causes poorly reversible inhibition of mTOR and inauces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 1999;59:886-894.
30. Garber K. Rapamycin's resurrection: A new way to target the cancer cell cycle. J Natl Cancer Institute. 2001;93:1517-1519.
31. Fluckiger AC, Garrone P, Durand I, Galizzi JP, Bancherau J. Interleukin 10 (IL-10) upregulates functional high affinity receptors on normal and leukemic B lymphocytes. J Exp Med. 1993;178:1473-1481.
32. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res. 1999;253:100-109.
33. Wagner EF, Hleb M, Hanna N, Sharma S. A pivotal role of cyclin D3 and cyclin-dependent kinase inhibitor p27 in the regulation of IL-2, IL-4- or IL-10-mediated human B cell proliferation. J Immunol. 1998;161:1123-1131.
34. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
35. Muthukkumar S, Ramesh TM, Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation. 1995;60:264-270.
36. Geoerger B, Kerr K, Tang CB, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 2001;61:1527-1532.
37. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene. 2000;19:6680-6686.
38. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A. 2001;98:10314-10319.
39. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70s6 kinase activity in Pten ± mice. Proc Natl Acad Sci U S A. 2001;98:10031-10033.
40. Grewe M, Gansauge F, Schmidt RM, Adler G, Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6k pathway in human pancreatic cancer cells. Cancer Research. 1999;59:3581-3587.
41. Brown EJ, Schreiner SL. A signaling pathway to translational control. Cell. 1996;86:517-520.
42. Jefferies HBJ, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′ TOP mRNA translation through inhibition of p70s6k. Embo J. 1997;16:3693-3704.
43. Li HL, Davis W, Pure E. Suboptimal cross-linking of antigen receptor induces Syk-dependent activation ofp70S6 kinase through protein kinase C and phosphoinositol 3 kinase. J Biol Chem. 1999;274:9812-9820.
44. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570-573.
45. 1 cyclins in primary T cells is not blocked by rapamycin or cyclosporin A. Int Immunol. 1993;5:1199-1209.
46. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis EN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem. 1998;273:29864-29872.
47. Feng LX, Ravindranath N, Dym M. Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia. J Biol Chem. 2000;275:25572-25576.
48. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998;18:753-761.
49. Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. P53/p21 (CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res. 2001;61:3373-3381.
50. Morice WG, Wiederrecht G, Brunn GJ, Siekierka JJ, Abraham RT. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. J Biol Chem. 1993;268:22737-22745.
51. Knudsen KE, Fribourg AF, Strobeck MW, Blanchard JM, Knudsen ES. Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest. J Biol Chem. 1999;274:27632-27641.
52. Kanwar JR, Shen WP, Rupinder KK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst. 2001;93:1541-1552.
53. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest. 2001;108:981-990.
54. Reed JC. The survivin saga goes in vivo. J Clin Invest. 2001;108:965-969.
55. Druker BJ, Lydon BN. Lessons learned from the development of an Abtyrosine inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105:3-7.
56. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (ST571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 2002;99:3792-3800.
57. Ishizuka T, Sakata N, Johnson GL, Gelfand EW, Terada N. Rapamycin potentiates dexamethasone-induced apoptosis and inhibits Jnk activity in lymphoblastoid cells. Biochem Biophys Res Com. 1997;230:386-391.
58. Guna M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med. 2002;8:128-135.
59. Chen H, Treweeke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood. 2000;96:3181-3187.
60. Aguayo A, O'Brian S, Keating M, et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood. 2000;96:768-770.
61. Marx SO, Marks AR. Bench to bedside: The development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852-855.
62. Groth CG, Backman L, Morales JM, et al. Sirolismus (rapamycin)-based therapy in human renal transplantation - Similar efficacy and different toxicity compared with cyclosporine: Sirolismus European Renal Transplant Study Group. Transplantation. 1999;67:1036-1042.
63. Pavletic ZS, Bierman PJ, Vos JM. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol. 1998;9:1023-1026.
64. Mills GB, Lu Y, Kohn EC. Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the P3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98:10031-10033.